F. Shen

Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma.

J. Xu, Zonghai Li, Yingyi Zhang, 2019, Journal of Clinical Oncology.